iQemo - Building Foundations for Global Growth: What We Learned in 2025

‍

As 2025 draws to a close, I always like to take a moment to reflect, whilst keeping a close eye on what the new year will bring.  

I joined iQ HealthTech in August 2025 and I was immediately struck by the company’s mission – the ‘why’. The purpose and drive were simple, to make SACT prescribing safer, simpler and more effective, and to fundamentally improve the workflows that lead to improved clinical and patient outcomes. This is embedded throughout the business, and I was humbled and energised to become part of this mission.  

2025 has also pushed me, challenged me, and taught me more about global oncology. What I’ve learned is simple: regardless of geography, clinicians everywhere want one thing and that is to deliver SACT safely, consistently and confidently.

2025 saw iQemo travel further than ever. Each stop taught us something essential about building the foundations for global expansion.

BOPA, COSA-IPOS and Global Health Exhibition weren’t just conferences for us.
They were proof points that the mission behind iQemo resonates globally.

BOPA – Strengthening our UK Foundation

The standout moment was our Head of Product, Bastiaan’s thought leadership on AI in cancer pharmacy. His session reinforced what the oncology pharmacy community has been telling us all year:

• AI belongs in SACT prescribing only when it is transparent, clinically aligned and trusted.

The response at BOPA showed that our UK foundation isn’t just strong, but it’s respected. This gives us a fantastic platform to build upon and introduce more organisations to iQemo.

‍

COSA-IPOS, Adelaide – Partnership Validation

Showcasing iQemo with Altera demonstrated something powerful:

• When oncology teams see iQemo as part of a connected ecosystem, something clicks.

Conversations with clinicians reinforced that fragmented and disparate systems are holding services and better outcomes back. Integrated, intelligent workflows are not a “nice to have” - they are essential to scale safely.

Global Health Exhibition, Riyadh – Understanding the GCC Opportunity

Riyadh was eye-opening. It gave us a fresh and intense perspective on a fast-moving region focused on clinical excellence and digital transformation.

What we gained:

• Market intelligence

• Regulatory insight

• The ‘Art of the Possible’ - a picture of how iQemo can support safer SACT services across the Middle East

Different markets. Different systems. But the same challenge: How do we safely deliver rising volumes of systemic anti-cancer therapy?

2025 - Our Strategic Takeaways

• Demand for better, safer SACT prescribing is a global priority.

• Our model is scalable, proven and adaptable across different markets.

• There is a lot of talk and noise, but clinicians value innovation grounded in clinical experience, not hype.

• Ecosystem-friendly design is a major differentiator.

Looking Ahead to 2026

• UK: Strengthen our foundations, keep building and increase our presence within oncology pharmacy

• ANZ: Accelerate ecosystem partnerships and expansion

• The GCC: Enter with intent, localisation and long-term alignment.

• Product: Advance AI-enabled safety automation, analytics and interoperability

‍

2025 gave us clarity. 2026 is about momentum. The world is ready for iQemo.

‍